Expression And Significance Of CXCL5 In Prostate Cancer

Background: Prostate cancer is one of the most prevalent malignacies affecting men worldwide. And the number of afflicted men is increasing rapidly. Recent studies indicate that Chemokines, a family of inflammation factors, are important mediators in tumorogenesis, progression, invasion and metastasis of prostate cancer. CXCL5 is a proangiogenic CXC-type chemokine that is an inflammatory mediator and a powerful attractant for granulocytic immune cells. CXCL5 is secreted by several cell types, including epithelial cells, endothelial cells, fibroblasts, neutrophils, monocytes, and macrophages. It has been shown that CXCL5 could promote the growth and metastasis of non-small cell lung cancer, gastric cancer and endometrial cancer. The current study is intended to observe the expression of CXCL5 in prostate cancer, and explore the role CXCL5 plays in the progression and metastasis of prostate cancer.Objective: Investigate the expression of CXCL5 in human prostate cancer. Analysis the expression result with the pathologic grading of cancer, clinical stage and tumor metastasis. And explore the role CXCL5 plays in the progression and metastasis of prostate cancer.Methods: Collect the cases of prostate cancer, PIN and benign prostatic hyperplasia from Oct, 2003 to Oct, 2008 in pathological department of Xiangya Hospital of Central South University. The expression of CXCL5 in prostate cancer (n=41 tissues), benign prostatic hyperplasia (n=14 tissues) and PIN (n=6 tissues) were detected by immunohistochemistry SP method. The CXCL5 expression was compared among these different tissues. The relationship between CXCL5 expression and related clinicopathologic features was statistically analyzed. Results: The immunohistochemistry detection of CXCL5 in paraffin slides indicates that the staining scores of CXCL5 in prostate cancer(10.02±2.055) was significant higher than that in non-cancer tissue(4.45±1.317) (P<0.05). The cases were classified by the Whitmore-Jewett staging system and graded according to Gleason grading system. The expression of CXCL5 was associated with pathological grades and clinical stages. The staining scores of CXCL5 in C+D stages were significant higher than that in A+B stages(P<0.05). The expression of CXCL5 in metastatic prostate cancer was higher than that in prostate cancer without metastasis (P<0.05).Conclusion: The expression of CXCL5 in prostate cancer was significant higher than that in benign prostatic hyperplasia and prostate intraepithelial neoplasia. And it was associated with pathological grade , clinical stage and tumor metastasis. CXCL5 may play a role in the progression and metastasis of prostate cancer.